Trial Profile
A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lomitapide (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Sponsors Aegerion Pharmaceuticals
- 01 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 May 2016 New trial record